CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 20 enrolled
Drug / intervention
Deferiprone delayed release tablet formulation +1 moredrug
Likely dose
Deferiprone delayed release tablet formulation 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02442310
NCT02442310Phase 1Completed
CompareCT.gov

Single Dose Crossover Comparative Bioavailability Study of Deferiprone 600 mg Delayed Release Tablets Versus Deferiprone Oral Solution in Healthy Male and Female Volunteers Following a 1200 mg Dose

ApoPharma·interventional·Posted May 13, 2015·Updated May 13, 2016

In Brief

A Phase 1 clinical trial evaluating Deferiprone delayed release tablet formulation and Deferiprone oral solution for Healthy. Completed, enrolled 20 participants across 1 site.

Detailed Summary

The purpose of this study is to look at the pharmacokinetics of a new formulation of deferiprone (deferiprone delayed release tablets) under fed and fasting conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesCanada
CollaboratorsAlgorithme Pharma Inc

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedMay 13, 2015
Enrollment StartMay 1, 2015
Primary CompletionJul 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 11.1 years ago

Interventions

Deferiprone delayed release tablet formulationdrug

Deferiprone 600 mg delayed release tablet formulation

Deferiprone oral solutiondrug

Deferiprone 100 mg/mL oral solution